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Abstract
Background: Disrupted and delayed Medicaid coverage has been consistently associated with lower rates of cancer screening
and early-stage cancer diagnosis compared with continuous coverage. However, the relationships between Medicaid coverage timing, breast cancer treatment delays, and survival are less clear. Methods: Using the linked Missouri Cancer RegistryMedicaid claims data, we identified 4583 women diagnosed with breast cancer between 2007 and 2016. We used logistic regression to estimate odds ratios (ORs) of late-stage diagnosis and treatment delays for prediagnosis (>30 days, >90 days, and
>1 year before diagnosis) vs peridiagnosis enrollment. Cox proportional hazards models were used to estimate the hazard ratio (HR) of breast cancer-specific mortality for pre- vs postdiagnosis enrollment. Results: Patients enrolled in Medicaid more
than 30 days before diagnosis were less likely to be diagnosed at a late stage compared with those enrolled in Medicaid
peridiagnosis (OR ¼ 0.69, 95% confidence interval [CI] ¼ 0.60 to 0.79). This result persisted using enrollment 90-day (OR ¼ 0.64,
95% CI ¼ 0.56 to 0.74) and 1-year thresholds (OR ¼ 0.55, 95% CI ¼ 0.47 to 0.65). We did not observe a difference in the likelihood
of treatment delays between the 2 groups. After adjustment for sociodemographic factors, there was no statistically
significant difference in the risk of breast cancer mortality for patients enrolled more than 30 days prediagnosis relative to
patients enrolled peridiagnosis (HR ¼ 0.98, 95% CI ¼ 0.83 to 1.14), but a lower risk was observed for patients enrolled
prediagnosis when using 90 days (HR ¼ 0.85, 95% CI ¼ 0.72 to 0.999) or 1 year (HR ¼ 0.79, 95% CI ¼ 0.66 to 0.96) as the threshold.
Conclusions: Women with breast cancer who enroll in Medicaid earlier may benefit from earlier diagnoses, but only longerterm enrollment may have survival benefits.

Breast cancer is the most commonly diagnosed cancer and second-leading cause of cancer-related death among women in the
United States (1). Despite improvements in screening and treatment that have reduced breast cancer mortality, disparities still
exist in early-stage diagnosis, treatment, and survival by geography, race and ethnicity, socioeconomic status (SES), and access to health insurance and preventive care (2-8). Given the
particularly high burden of breast cancer among uninsured,
low-SES women, programs such as Medicaid are important for
improving cancer screening, treatment, and outcomes.
Following the implementation of the Affordable Care Act,
Medicaid-expanding states saw greater decreases in uninsured
rates and advanced-stage breast cancer diagnoses compared
with non–Medicaid-expanding states (9). Furthermore,

Medicaid-expanding states saw larger increases in screening
mammography rates among low-income women compared
with nonexpansion states (10). Among Hispanic and nonHispanic Black breast cancer survivors, the risk of being uninsured decreased and mammogram usage increased after
Medicaid expansion (11).
Although Medicaid-insured patients have better survival
than uninsured patients, they present with more advancedstage breast cancer and poorer survival than privately insured
patients (12-18). Medicaid-insured patients also have lower
breast cancer screening rates and larger time gaps between
mammograms (19). These findings may be partly explained by
less coverage continuity under Medicaid compared with private
insurance. In many states, patients may not become eligible for
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Methods
Study Population
We used Medicaid administrative claims to identify women enrolled in the fee-for-service program and diagnosed with invasive breast cancer in Missouri between 2007 and 2016. Medicaid
claims contain emergency, inpatient, and outpatient services
and prescription drugs. We then linked claims of identified
cases to the Missouri Cancer Registry data using Link Plus V. 2.0
(Centers for Disease Control and Prevention). Following the data
collection and coding rules set by the National Program of
Cancer Registries, the Missouri Cancer Registry collects data on
demographic factors (race, ethnicity, age, marital status, sex),
address at time of diagnosis, tumor characteristics (date of diagnosis, primary site, tumor grade, tumor size), and tumordirected treatment modalities (surgery, radiotherapy, chemotherapy, and hormone therapy) and their start dates for more
than 95% of incident cases in Missouri. A probabilistic matching
approach was used, and matching variables included unique
departmental control numbers, first and last name, social security number, date of birth, and race or ethnicity (22). The study
was approved by the institutional review board at Washington
University School of Medicine in St. Louis, the Missouri
Department of Health and Senior Services, and the Missouri
Department of Social Services.
We identified 4583 women aged 18-65 years who were enrolled in Medicaid and diagnosed with breast cancer between
January 1, 2007, and December 31, 2015. We excluded patients
with missing stage at diagnosis (n ¼ 41) from the analysis of
late-stage diagnosis and patients with missing treatment time
information (n ¼ 59) from the analysis of treatment delay.

their diagnosis or later, we considered her “enrolled peridiagnosis.” We made this determination partly because 1
month was a common cutoff point in similar research in other
states (23-26), and MO HealthNet applications typically take up
to 30 days for approval. However, we also used 90 days and 1
year as cutoff points (used in similar research) to define
“enrolled before diagnosis” (27-30).

Late-Stage Diagnosis, Treatment Delays, and Breast
Cancer-Specific Mortality
Stage at diagnosis was coded as I to IV based on the eighth edition of American Joint Committee on Cancer Staging Atlas, and
stages III and IV were considered late stages. Treatment was
considered delayed if the number of days from diagnosis to any
treatment (including definitive surgery, radiation therapy, chemotherapy, and endocrine therapy) was greater than 60, based
on research showing statistically significantly higher mortality
risk associated with treatment delays longer than 60 days (31).
Missouri’s state vital records and the National Death Index were
used to determine patients’ vital status, and death certificates
were used to identify a single, disease-specific underlying cause
of death. Individual data were censored if death occurred by
causes other than breast cancer or if the individual survived beyond the end of the study period. We calculated follow-up time
from the date of diagnosis to the date of whichever of the following events occurred first: death, last contact, or December
31, 2016.

Covariates
Sociodemographic variables included age (continuous), race
(non-Hispanic Black, non-Hispanic White, non-Hispanic Black,
or others [including Asian, Hispanic and unknown]), and marital status (married or domestic partner; unmarried, divorced,
separated, or widowed; or missing). We examined 10 neighborhood-level socioeconomic covariates based on residential census tracts of patients at the time of diagnosis, including
proportions of the population that were African American, below the FPL, without a high school diploma, unemployed, living
in renter-occupied housing, living in single-parent households,
without a car, and aged 65 years and older, as well as median
household income and median home value. The census tract–
level covariates were obtained from 2010 Census estimates
based on 2005-2009 (for cases with 2000 residential census tract
code available) and 2008-2012 (for cases with 2010 residential
census tract code available) American Community Survey data
and categorized using their quartiles across the state of
Missouri. Tumor characteristics included tumor size (<20 mm,
20-49 mm, 50 mm, or missing), grade (well-differentiated, intermediate, poor, or missing), and subtype (hormone receptor–
positive, hormone receptor–negative, or missing). Treatment
variables were coded based on whether patients received definitive surgery (no surgery, surgery, or missing), chemotherapy
(yes, no, or missing), radiation (yes, no, or unknown), and hormone therapy (yes, no, or unknown).

Statistical Analyses
Medicaid Enrollment
If a patient was enrolled in Medicaid more than 30 days before
the date of cancer diagnosis, we referred to her as “enrolled before diagnosis.” If a patient was enrolled within 30 days before

To examine the relationship between Medicaid enrollment time
and late-stage diagnosis and treatment delay, we used logistic
regression to estimate odds ratios (ORs) and associated 95%
confidence intervals (CIs). The analysis of late-stage diagnosis
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Medicaid until after a new cancer diagnosis and consequently
may not benefit from regular screening and preventive care
afforded to those with continuous coverage. Disrupted and
delayed Medicaid coverage have been consistently associated
with lower rates of cancer screening and greater likelihood of
advanced-stage cancer than continuous coverage (20). However,
the relationships between Medicaid coverage timing and breast
cancer treatment delays and survival are less clear.
Therefore, we examined associations between timing of
Medicaid enrollment relative to breast cancer diagnosis and
late-stage diagnosis, treatment delays, and survival in Missouri,
which had not yet expanded Medicaid in the study period of
2007-2016. Before the implementation of Medicaid expansion in
October 2021, nondisabled adults with children qualified for MO
HealthNet (Missouri Medicaid) if their incomes were at or below
21% of the federal poverty level (FPL) (21). Low-income adults
can also qualify for Medicaid if they are living with a disability,
blind, pregnant, or older than age 65 years. Additionally,
through Missouri’s Show Me Healthy Women (Breast and
Cervical Cancer Control [BCCCP]) Program, uninsured women
aged 35-65 years with incomes at or below 200% of FPL can receive breast and cervical cancer screening and, if diagnosed
with breast and/or cervical cancer, may then become eligible for
Medicaid to cover cancer treatment.
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Results
Of the 4583 cases, 28.2% were non-Hispanic Black people, 69.8%
were non-Hispanic White people, and 2% were people of other
races and ethnicities. Most were unmarried (67.6%) and enrolled
in Medicaid more than 30 days prediagnosis (52.9%) (Table 1).
The mean age was 51.5 years. At the time of diagnosis, most
women lived in census tracts above the median in terms of percentages of the population below the FPL (63.7%), without a high
school diploma (60.2%), unemployed (63.7%), living in renteroccupied housing units (59.2%), and living in single-parent
households with children (61.7%). Compared with patients enrolled peridiagnosis, patients enrolled in Medicaid more than
30 days prediagnosis were more likely to be non-Hispanic Black
(29.7% vs 26.5%), unmarried (73.4% vs 61.1%), disabled or blind
(75.5% vs 22.8%), and living in a census tract in the highest quartile in terms of percentage of population below the FPL (36.7% vs
30.7%). Patients enrolled prediagnosis were also less likely to
participate in the BCCCP (12.7% vs 74.5%) and receive radiation
therapy (56.6% vs 63.4%), chemotherapy (54.6% vs 71.2%), or hormone therapy (49.4% vs 53.2%). There was no statistically significant age difference between the 2 groups.
Late-stage diagnosis accounted for 22.7% of patients enrolled
in Medicaid longer than 30 days prediagnosis and 29.6% of
patients enrolled peridiagnosis. Patients enrolled longer than
30 days prediagnosis were less likely to be diagnosed at a late
stage compared with those enrolled peridiagnosis (OR ¼ 0.69,
95% CI ¼ 0.60 to 0.79). This result held when we defined
“enrolled before diagnosis” as being enrolled in Medicaid longer
than 90 days (OR ¼ 0.64, 95% CI ¼ 0.56 to 0.74) or 1 year before diagnosis (OR ¼ 0.55, 95% CI ¼ 0.47 to 0.65) (Figure 1,
Supplementary Tables 1 and 2, available online).
Overall, 16.5% of patients enrolled in Medicaid longer than
30 days prediagnosis and 17.9% of patients enrolled peridiagnosis experienced treatment delays longer than 60 days. There
was no statistically significant difference in the likelihood of
treatment delays between the 2 groups using 30 days (OR ¼ 0.93,
95% CI ¼ 0.80 to 1.10), 90 days (OR ¼ 1.00, 95% CI ¼ 0.85 to 1.18), or
1 year (OR ¼ 0.93, 95% CI ¼ 0.77 to 1.12) as the cutoff to define
“enrolled before diagnosis” (Figure 2, Supplementary Tables 1
and 2, available online).
During an average 52-month follow-up, 939 (20.5%) patients
died, of which 650 (14.2%) died from breast cancer. There was
no statistically significant difference in the hazard ratio (HR) of
breast cancer–specific mortality for patients enrolled in
Medicaid longer than 30 days before diagnosis relative to
patients enrolled peridiagnosis (HR ¼ 0.98, 95% CI ¼ 0.84 to 1.14).
Adjustment for individual and neighborhood sociodemographic
factors did not change the risk (HR ¼ 0.98. 95% CI ¼ 0.83 to 1.14).

After adjusting additionally for cancer stage and other tumor
characteristics, patients enrolled longer than 30 days before diagnosis had higher risk of mortality compared with patients enrolled peridiagnosis (HR ¼ 1.35, 95% CI ¼ 1.15 to 1.58) (Figure 3;
Supplementary Table 3, available online). Further adjustment
for treatment did not statistically significantly change the risk
(HR ¼ 1.33, 95% CI ¼ 1.13 to 1.56) (Supplementary Figure 1, available online). Using a 90-day cutoff point to define pre- and peridiagnosis enrollment, we found patients enrolled prediagnosis
had lower risk of mortality compared with those enrolled peridiagnosis (HR ¼ 0.85, 95% CI ¼ 0.72 to 0.99) after adjustment for
individual and census tract–level sociodemographic factors.
Further adjustment for tumor characteristics alone (Figure 3) or
with treatment (Supplementary Figure 1, available online) increased the hazard ratio to 1.20 (95% CI ¼ 1.01 to 1.41) and 1.16
(95% CI ¼ 0.98 to 1.37), respectively. Similarly, enrollment longer
than a year before diagnosis was associated with lower mortality risk after adjustment for sociodemographic factors
(HR ¼ 0.79, 95% CI ¼ 0.66 to 0.96). This association became statistically non-significant after further adjustment for tumor characteristics (HR ¼ 1.20, 95% CI ¼ 0.99 to 1.46) (Figure 3) and
treatment (HR ¼ 1.15, 95% CI ¼ 0.95 to 1.41) (Supplementary
Figure 1, available online).

Discussion
In this study, we compared the likelihoods of late-stage diagnoses and treatment delays and survival of patients enrolled in
Medicaid before or around a breast cancer diagnosis. Patients
enrolled in Medicaid prediagnosis were less likely to be diagnosed at late stages. There was no statistically significant association between enrollment time and risk of treatment delays
longer than 60 days. Importantly, longer than 90 days or 1 year
of enrollment before cancer diagnosis was associated with
lower risk of breast cancer–specific mortality when adjusting
for sociodemographic factors alone, which disappeared or reversed after further adjustment for tumor characteristics. This
suggests a potential confounding effect of tumor severity.
Breast cancer mortality is more strongly influenced by pathological characteristics than Medicaid enrollment timing, particularly when the difference in durations of enrollment is shorter,
such that adjustment for tumor factors leads to apparent reversal of the effects of Medicaid enrollment timing. Alternatively,
this finding suggests earlier enrollment may reduce mortality
by means of earlier diagnoses, because earlier insurance coverage allows patients better access to screening, prompt followup, and identification of tumors at earlier stages. Interestingly,
longer durations of Medicaid coverage before diagnosis
appeared to be associated with greater protective effects, with
the odds ratio for late-stage diagnosis and the hazard ratio of
breast cancer mortality decreasing as the time threshold for
pre- vs peridiagnosis Medicaid enrollment increased from more
than 30 days to 90 days to 1 year. Collectively, this suggests that
patients who enroll in Medicaid earlier may benefit from earlier
diagnoses of less aggressive tumors, but only longer-term continuous Medicaid enrollment may provide survival benefits.
Our findings align with previous research showing patients
enrolling in Medicaid after a cancer diagnosis are more likely to
be diagnosed at later stages, with more aggressive tumor subtypes compared with those enrolled before diagnosis (23,24,2729,32). To our knowledge, however, only 1 study has examined
the relationship between Medicaid enrollment timing and treatment delays, showing a higher likelihood of treatment delays
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was adjusted for age, race or ethnicity, marital status, and census tract–level socioeconomic variables. The analysis of treatment delays was further adjusted for tumor characteristics.
We used Cox proportional hazards regression to examine
the relationship between Medicaid enrollment time and risk of
breast cancer mortality. The proportional hazards assumption
was examined visually using Kaplan-Meier curves. The model
was first adjusted for individual and census tract–level socioeconomic characteristics, then further adjusted for tumor characteristics. The final model was further adjusted for treatment.
All analyses were performed in the R statistical programming environment. A 2-sided P less than .05 was considered statistically significant.
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Table 1. Characteristics of women diagnosed with breast cancer in Missouri from 2007 to 2015 by relative time of enrollment in Medicaid
(n ¼ 4583)
Characteristics

Enrolled peridiagnosisb

Total

2424 (52.9)
51.7 (9.0)

2159 (47.1)
51.2 (8.3)

4583
51.5 (8.7)

29.7
68.6
1.6

26.5
71.0
2.5

28.2
69.8
2.0

24.4
73.4
2.2
75.5
12.7

37.2
61.1
1.7
22.8
74.5

30.4
67.6
1.9
50.7
41.8

10.1
21.9
29.4
36.7

15.4
22.2
30.2
30.7

12.6
22.0
29.8
33.9

12.7
24.2
30.8
30.4

14.6
24.9
29.9
29.2

13.6
24.5
30.4
29.8

14.2
19.7
26.4
37.9

15.1
20.4
28.1
35.0

14.6
20.0
27.2
36.5

13.0
23.0
30.8
31.4

19.2
23.4
31.3
24.6

15.9
23.2
31.0
28.2

11.8
21.9
26.7
37.5

15.9
23.7
25.6
33.4

13.8
22.8
26.2
35.6

13.2
21.7
27.6
35.6

18.2
23.1
25.8
31.4

15.6
22.3
26.8
33.7

22.4
19.6
20.2
35.9

23.5
20.9
20.4
33.7

23.0
20.2
20.3
34.9

24.4
24.7
25.9
23.1

25.4
26.3
25.9
21.0

24.9
25.4
25.9
22.1

36.4
29.3
21.9
10.4

31.4
29.9
23.2
14.0

34.1
29.6
22.5
12.1

34.5
29.8
22.7
10.9

30.7
29.6
24.3
14.0

32.7
29.7
23.4
12.4
(continued)
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No. of cases (%)
Age, mean (SD), y
Race and ethnicity, %
Non-Hispanic Black
Non-Hispanic White
Otherc
Marital status, %
Married
Unmarried
Unknown
Blind or disabled classification, %
BCCCP participation, %
Population under federal poverty lined, %
Quartile 1 (<7.43)
Quartile 2 (7.43 to <13.24)
Quartile 3 (13.24 to <21.10)
Quartile 4 (21.10)
Population without high school diplomad, %
Quartile 1 (<2.16)
Quartile 2 (2.16 to <4.21)
Quartile 3 (4.21 to <7.08)
Quartile 4 (7.08)
Unemployedd, %
Quartile 1 (<4.18)
Quartile 2 (4.18 to <6.20)
Quartile 3 (6.20 to <9.68)
Quartile 4 (9.68)
Living in renter-occupied housing unitsd, %
Quartile 1 (<17.42)
Quartile 2 (17.42 to <27.46)
Quartile 3 (27.46 to <43.05)
Quartile 4 (43.05)
Single-parent households with childrend, %
Quartile 1 (<20.33)
Quartile 2 (20.33 to <30.84)
Quartile 3 (30.84 to <46.67)
Quartile 4 (46.67)
Population with no card, %
Quartile 1 (<2.86)
Quartile 2 (2.86 to <5.47)
Quartile 3 (5.47 to <10.44)
Quartile 4 (10.44)
Population African Americand, %
Quartile 1 (<0.38)
Quartile 2 (0.38 to <2.64)
Quartile 3 (2.64 to <11.40)
Quartile 4 (11.40)
Population aged 65 yd, %
Quartile 1 (<9.67)
Quartile 2 (9.67 to <13.23)
Quartile 3 (13.23 to <17.20)
Quartile 4 (17.20)
Median household incomed, %
Quartile 1 (<$39 911)
Quartile 2 ($39 911 to <$51 258)
Quartile 3 ($51 258 to <$66 283)
Quartile 4 ($66 283)
Median home valued, %
Quartile 1 (<$82 500)
Quartile 2 ($82 500 to <$113 600)
Quartile 3 ($113 600 to <$157 000)
Quartile 4 ($157 000)

Enrolled before diagnosisa
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Table 1. (continued)
Characteristics

Enrolled peridiagnosisb

13.6
30.0
33.0
14.0
8.4
1.0

9.1
21.5
39.2
18.6
10.8
0.7

11.5
26.0
35.9
16.2
9.5
0.9

43.2
31.8
10.9
14.2

34.4
38.7
16.0
10.9

39.1
35.0
13.3
12.6

16.4
34.8
40.8
8.0

13.7
36.0
44.7
5.6

15.1
35.4
42.6
6.9

74.5
21.4
4.1

72.3
24.7
3.1

73.4
23.0
3.6

92.7
6.8
0.5

92.5
7.1
0.4

92.6
7.0
0.4

56.6
42.0
1.4

63.4
36.0
0.6

59.8
39.2
1.0

54.6
43.1
2.3

71.2
27.7
1.2

62.4
35.8
1.7

49.4
35.8
14.8

53.2
36.6
10.2

51.2
36.2
12.7

Total

a

Enrolled in Medicaid for longer than 30 days before the date of cancer diagnosis. BCCCP ¼ Breast and Cervical Cancer Control Program; ER ¼ estrogen receptor; PR ¼
progesterone receptor.

b

Enrolled in Medicaid within 30 days before their cancer diagnosis or later.

c

Including Asian, Hispanic, and unknown.

d
Characteristics of census tract where patient was living at cancer diagnosis. Overall, census tract code was missing for 1.7% of patients, including 1.9% of patients enrolled before diagnosis and 1.4% or less of patients enrolled after diagnosis.

Figure 1. Odds ratios (ORs) of late-stage diagnosis in women with breast cancer enrolled in Medicaid before diagnosis compared with those enrolled peridiagnosis.
Late-stage diagnosis included stages III-IV. The analysis was adjusted for age, race, marital status, and socioeconomic characteristics of census tracts. CI ¼ confidence
interval.
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Cancer stage, %
0
I
II
III
IV
Unknown
Tumor size, %
20 mm
21-50 mm
>50 mm
Unknown
Tumor grade, %
Well differentiation
Intermediate differentiation
Poor differentiation
Unknown
Tumor subtype, %
ERþ or PRþ
ER and PR
Unknown
Surgical treatment, %
Yes
No
Unknown
Radiation therapy, %
Yes
No
Unknown
Chemotherapy, %
Yes
No
Unknown
Hormone therapy, %
Yes
No
Unknown

Enrolled before diagnosisa
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age, race, marital status, socioeconomic characteristics of census tracts, tumor stage, size, grade, and hormone receptor subtypes. CI ¼ confidence interval.

Figure 3. Hazard ratios (HRs) of breast cancer–specific mortality in women with breast cancer enrolled in Medicaid before diagnosis compared with those enrolled peridiagnosis. aThe analysis was not adjusted for any covariates. bThe analysis was adjusted for age, race, marital status, and socioeconomic characteristics of census
tracts. cThe analysis was further adjusted for tumor stage, size, grade, and hormone receptor subtypes. CI ¼ confidence interval.

for breast, cervical, and colorectal cancers in new Medicaid
enrollees than longer-term enrollees (32). However, patients in
that study were enrolled in managed care and fee-for-service
programs, the latter of which was associated with higher odds
for treatment delays. In our study, all patients were enrolled in
fee-for-service programs, and Medicaid enrollment time was
not related to treatment delays. Therefore, Medicaid program
type should be considered in studies of impacts of Medicaid
coverage timing on treatment initiation.
Few studies have examined the relationship between
Medicaid coverage duration and breast cancer survival and with
inconsistent results. In New Jersey, newly enrolled Medicaid
patients with breast cancer had lower 2-year survival than
patients enrolled more than 6 months before breast cancer diagnosis. However, the analysis was not adjusted for sociodemographic factors and Medicaid program type (fee for service vs
managed care) (32). Bradley et al. (26) found no difference in
mortality risk between patients enrolled in Medicaid 1 month
and longer prediagnosis and those enrolled peridiagnosis in
Michigan, which resembled our findings when using 30 days as
the threshold for pre- and peridiagnosis coverage. Koroukian et
al. (28) used longer than 3 months to define prediagnosis
Medicaid coverage in Ohio and observed similar breast cancer
mortality risk between pre- and peridiagnosis enrollment after
adjustment for sociodemographic factors and cancer stage.
However, this null finding might be driven by adjustment for
cancer stage because late-stage diagnosis was more likely to occur in patients enrolled in Medicaid peridiagnosis.
There are several potential explanations for associations between earlier Medicaid enrollment and earlier-stage diagnoses

and better survival. Earlier insurance coverage may allow better
access to screening mammography and primary care (10,33,34),
permitting prompter diagnoses, patient education, and management of concurrent illnesses (35,36). Increased primary care
visits are associated with lower breast cancer mortality, mediated partly by earlier-stage diagnoses (37). Uninsured women
may not present for medical care until experiencing symptoms,
at which time their cancer may have progressed to a later stage.
Lack of insurance coverage may also limit patients’ ability to obtain tumor biopsies and scans needed for diagnosis in the first
place, so later Medicaid coverage may directly delay cancer
workups.
Although not included in our analyses, BCCCP participation
may have been associated with treatment delay and mortality.
Patients who enrolled in Medicaid peridiagnosis were more
likely to be BCCCP participants than were patients enrolled prediagnosis (74.5% vs 12.7%). The frequent delays associated with
the process itself of applying for and being accepted by Missouri
Medicaid (even after eligibility criteria are met) make it more
likely that BCCCP participants do not enroll until at least the
time around or after diagnosis. Compared with BCCCP participants, Medicaid enrollees who qualify under traditional eligibility categories have much lower incomes (21% vs 200% of the
FPL) and are less likely to be disabled or blind. Consequently,
BCCCP participants have relatively more financial resources
and fewer comorbidities than patients who qualify outside of
BCCCP, which could decrease risks of treatment delays and
mortality independently of Medicaid enrollment timing and
thus impact associations between Medicaid enrollment timing
and these outcomes.
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Figure 2. Odds ratios (ORs) of treatment delays in women with breast cancer enrolled in Medicaid before diagnosis compared with those enrolled peridiagnosis.
Treatment delays were defined as more than 60 days from diagnosis to surgery, radiation therapy, chemotherapy, or hormone therapy. The analysis was adjusted for
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